<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font23 { font-size : 23; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font31 { font-size : 31; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font31">virus </span>
   <span class="font23">viral </span>
   <span class="font19">levels </span>
   <span class="font19">HIV </span>
   <span class="font18">antiviral </span>
   <span class="font18">day </span>
   <span class="font18">HBV </span>
   <span class="font18">high </span>
   <span class="font17">activity </span>
   <span class="font17">vaccine </span>
   <span class="font17">cell </span>
   <span class="font16">HCV </span>
   <span class="font16">compounds </span>
   <span class="font15">ICAR </span>
   <span class="font15">Figure </span>
   <span class="font15">resistance </span>
   <span class="font15">work </span>
   <span class="font15">clinical </span>
   <span class="font15">group </span>
   <span class="font15">{border-style </span>
   <span class="font14">RNA </span>
   <span class="font14">drug </span>
   <span class="font14">good </span>
   <span class="font14">DNA </span>
   <span class="font14">active </span>
   <span class="font14">immune </span>
   <span class="font14">px;} </span>
   <span class="font14">safety </span>
   <span class="font14">#ffffff;} </span>
   <span class="font14">Antiviral </span>
   <span class="font14">University </span>
   <span class="font14">days </span>
   <span class="font14">infected </span>
   <span class="font14">patients </span>
   <span class="font14">used </span>
   <span class="font14">vaccinated </span>
   <span class="font14">RV-C </span>
   <span class="font14">low </span>
   <span class="font14">nucleoside/tide </span>
   <span class="font14">study </span>
   <span class="font13">Mike </span>
   <span class="font13">culture </span>
   <span class="font13">different </span>
   <span class="font13">known </span>
   <span class="font13">mice </span>
   <span class="font13">placebo </span>
   <span class="font13">log </span>
   <span class="font13">new </span>
   <span class="font13">potential </span>
   <span class="font13">therapy </span>
   <span class="font13">using </span>
   <span class="font13">years </span>
   <span class="font13">However, </span>
   <span class="font13">combination </span>
   <span class="font13">cure </span>
   <span class="font13">highly </span>
   <span class="font13">resistant </span>
   <span class="font13">target </span>
   <span class="font13">disease </span>
   <span class="font13">drugs </span>
   <span class="font13">genetic </span>
   <span class="font13">having </span>
   <span class="font13">infection </span>
   <span class="font13">transmission </span>
   <span class="font13">type </span>
   <span class="font12">ISAR </span>
   <span class="font12">International </span>
   <span class="font12">Maaike </span>
   <span class="font12">Zika </span>
   <span class="font12">administered </span>
   <span class="font12">human </span>
   <span class="font12">inhibitors </span>
   <span class="font12">set </span>
   <span class="font12">sofosbuvir </span>
   <span class="font12">transmitted </span>
   <span class="font12">uridine </span>
   <span class="font12">-del </span>
   <span class="font12">Cys </span>
   <span class="font12">David </span>
   <span class="font12">PSI- </span>
   <span class="font12">cells </span>
   <span class="font12">dengue </span>
   <span class="font12">fusion </span>
   <span class="font12">hepatitis </span>
   <span class="font12">included </span>
   <span class="font12">mutations </span>
   <span class="font12">pocket </span>
   <span class="font12">profile </span>
   <span class="font12">selection </span>
   <span class="font12">time </span>
   <span class="font12">vRC </span>
   <span class="font12">viraemia </span>
   <span class="font12">Ann </span>
   <span class="font12">Award </span>
   <span class="font12">Keynote </span>
   <span class="font12">Phase </span>
   <span class="font12">Research </span>
   <span class="font12">Tyr </span>
   <span class="font12">USA </span>
   <span class="font12">antibody </span>
   <span class="font12">assay </span>
   <span class="font12">comments </span>
   <span class="font12">detected </span>
   <span class="font12">effective </span>
   <span class="font12">identified </span>
   <span class="font12">important </span>
   <span class="font12">newly </span>
   <span class="font12">poliovirus </span>
   <span class="font12">replication </span>
   <span class="font12">respectively. </span>
   <span class="font12">virus. </span>
   <span class="font12">weeks </span>
   <span class="font12">(%) </span>
   <span class="font12">CDHR </span>
   <span class="font12">Conference </span>
   <span class="font12">IFN </span>
   <span class="font12">Pharmasset </span>
   <span class="font12">Therefore, </span>
   <span class="font12">ZIKA </span>
   <span class="font12">analogues </span>
   <span class="font12">barrier </span>
   <span class="font12">compound </span>
   <span class="font12">early </span>
   <span class="font12">efficacy </span>
   <span class="font12">group, </span>
   <span class="font12">groups </span>
   <span class="font12">host </span>
   <span class="font12">including </span>
   <span class="font12">inhibitor </span>
   <span class="font12">just </span>
   <span class="font12">meeting </span>
   <span class="font12">modern </span>
   <span class="font12">polio </span>
   <span class="font12">px; </span>
   <span class="font12">rate </span>
   <span class="font12">research </span>
   <span class="font12">undetectable </span>
   <span class="font12">various </span>
   <span class="font12">viruses </span>
   <span class="font12">years. </span>
   <span class="font12">{font-family </span>
   <span class="font11">ARB- </span>
   <span class="font11">Elion </span>
   <span class="font11">ICAR, </span>
   <span class="font11">ICAR. </span>
   <span class="font11">Priscilla </span>
   <span class="font11">RV-A </span>
   <span class="font11">appeared </span>
   <span class="font11">approach </span>
   <span class="font11">binding </span>
   <span class="font11">challenge. </span>
   <span class="font11">control </span>
   <span class="font11">data </span>
   <span class="font11">decrease </span>
   <span class="font11">did </span>
   <span class="font11">discovered </span>
   <span class="font11">doses </span>
   <span class="font11">dosing </span>
   <span class="font11">focus </span>
   <span class="font11">followed </span>
   <span class="font11">font-size </span>
   <span class="font11">individuals </span>
   <span class="font11">lecture </span>
   <span class="font11">major </span>
   <span class="font11">mouse </span>
   <span class="font11">patients, </span>
   <span class="font11">point </span>
   <span class="font11">possible </span>
   <span class="font11">presented </span>
   <span class="font11">prodrug </span>
   <span class="font11">protein </span>
   <span class="font11">range </span>
   <span class="font11">reduction </span>
   <span class="font11">response </span>
   <span class="font11">retained </span>
   <span class="font11">shown </span>
   <span class="font11">similar </span>
   <span class="font11">small </span>
   <span class="font11">studies </span>
   <span class="font11">tested </span>
   <span class="font11">year, </span>
   <span class="font11">Atlanta, </span>
   <span class="font11">Eric </span>
   <span class="font11">FMCA </span>
   <span class="font11">GA, </span>
   <span class="font11">Gilead </span>
   <span class="font11">OPV </span>
   <span class="font11">Sofia </span>
   <span class="font11">Vere </span>
   <span class="font11">ZIKV </span>
   <span class="font11">activity, </span>
   <span class="font11">added </span>
   <span class="font11">asthma </span>
   <span class="font11">attenuated </span>
   <span class="font11">capsid </span>
   <span class="font11">cases </span>
   <span class="font11">cccDNA </span>
   <span class="font11">chronic </span>
   <span class="font11">confirmed </span>
   <span class="font11">corresponding </span>
   <span class="font11">countries </span>
   <span class="font11">described </span>
   <span class="font11">double; </span>
   <span class="font11">drugs, </span>
   <span class="font11">entry </span>
   <span class="font11">escape </span>
   <span class="font11">gave </span>
   <span class="font11">genotypes </span>
   <span class="font11">inhibit </span>
   <span class="font11">inhibition </span>
   <span class="font11">investigate </span>
   <span class="font11">lead </span>
   <span class="font11">led </span>
   <span class="font11">liver </span>
   <span class="font11">male </span>
   <span class="font11">measured </span>
   <span class="font11">medical </span>
   <span class="font11">mice, </span>
   <span class="font11">mutation </span>
   <span class="font11">obtained </span>
   <span class="font11">personal </span>
   <span class="font11">phosphoramidate </span>
   <span class="font11">positive </span>
   <span class="font11">preventing </span>
   <span class="font11">public </span>
   <span class="font11">received </span>
   <span class="font11">reduce </span>
   <span class="font11">report </span>
   <span class="font11">resistance. </span>
   <span class="font11">results </span>
   <span class="font11">severe </span>
   <span class="font11">subjects </span>
   <span class="font11">titres </span>
   <span class="font11">use </span>
   <span class="font11">vaccines </span>
   <span class="font11">viruses. </span>
   <span class="font11">year </span>
   <span class="font11">years, </span>
   <span class="font11">(n = ) </span>
   <span class="font11">Also, </span>
   <span class="font11">Following </span>
   <span class="font11">HBV. </span>
   <span class="font11">Hodge </span>
   <span class="font11">Mark </span>
   <span class="font11">Pei-Yong </span>
   <span class="font11">USA, </span>
   <span class="font11">WIS </span>
   <span class="font11">aim </span>
   <span class="font11">approved </span>
   <span class="font11">assessed </span>
   <span class="font11">bioavailability </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cellular </span>
   <span class="font11">challenged </span>
   <span class="font11">challenged-placebo </span>
   <span class="font11">chemistry </span>
   <span class="font11">cleared </span>
   <span class="font11">collaboration </span>
   <span class="font11">combined </span>
   <span class="font11">compounds, </span>
   <span class="font11">continued </span>
   <span class="font11">copies </span>
   <span class="font11">detectable </span>
   <span class="font11">discovery </span>
   <span class="font11">diversity </span>
   <span class="font11">does </span>
   <span class="font11">door </span>
   <span class="font11">dose </span>
   <span class="font11">effect </span>
   <span class="font11">evaluation </span>
   <span class="font11">example, </span>
   <span class="font11">given </span>
   <span class="font11">gives </span>
   <span class="font11">giving </span>
   <span class="font11">group. </span>
   <span class="font11">half-life </span>
   <span class="font11">higher </span>
   <span class="font11">iVDPV </span>
   <span class="font11">impact </span>
   <span class="font11">improved </span>
   <span class="font11">individual </span>
   <span class="font11">l-BHDU </span>
   <span class="font11">levels. </span>
   <span class="font11">likely </span>
   <span class="font11">long </span>
   <span class="font11">mice. </span>
   <span class="font11">modest </span>
   <span class="font11">need </span>
   <span class="font11">particles </span>
   <span class="font11">period </span>
   <span class="font11">present </span>
   <span class="font11">profile. </span>
   <span class="font11">projects </span>
   <span class="font11">reported </span>
   <span class="font11">respectively). </span>
   <span class="font11">solid; </span>
   <span class="font11">started </span>
   <span class="font11">strains </span>
   <span class="font11">strategy </span>
   <span class="font11">structural </span>
   <span class="font11">system. </span>
   <span class="font11">target-based </span>
   <span class="font11">testis </span>
   <span class="font11">therapy. </span>
   <span class="font11">vaccine. </span>
   <span class="font11">values </span>
   <span class="font11">versus </span>
   <span class="font11">virions </span>
   <span class="font11">virus, </span>
   <span class="font11">viruses, </span>
   <span class="font11">vivo </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">--, </span>
   <span class="font11">Antonín </span>
   <span class="font11">DOT </span>
   <span class="font11">Emory </span>
   <span class="font11">FMCA-P </span>
   <span class="font11">Holý </span>
   <span class="font11">Lecture: </span>
   <span class="font11">Meeting </span>
   <span class="font11">Memorial </span>
   <span class="font11">PSI--TP </span>
   <span class="font11">PhD </span>
   <span class="font11">Prusoff </span>
   <span class="font11">RV-B, </span>
   <span class="font11">SVR </span>
   <span class="font11">UAB </span>
   <span class="font11">University, </span>
   <span class="font11">VLs </span>
   <span class="font11">Viraemia </span>
   <span class="font11">West </span>
   <span class="font11">William </span>
   <span class="font11">Yang </span>
   <span class="font11">able </span>
   <span class="font11">accounts </span>
   <span class="font11">ancient </span>
   <span class="font11">antibodies </span>
   <span class="font11">antigens </span>
   <span class="font11">article </span>
   <span class="font11">assay. </span>
   <span class="font11">associated </span>
   <span class="font11">baseline </span>
   <span class="font11">bold </span>
   <span class="font11">challenge </span>
   <span class="font11">closed </span>
   <span class="font11">comparable </span>
   <span class="font11">compounds. </span>
   <span class="font11">concept </span>
   <span class="font11">containing </span>
   <span class="font11">contrast, </span>
   <span class="font11">copies/ml </span>
   <span class="font11">couples </span>
   <span class="font11">courier; </span>
   <span class="font11">critical </span>
   <span class="font11">current </span>
   <span class="font11">deletion </span>
   <span class="font11">development </span>
   <span class="font11">drugs. </span>
   <span class="font11">em; </span>
   <span class="font11">enable </span>
   <span class="font11">end </span>
   <span class="font11">exacerbations </span>
   <span class="font11">factors </span>
   <span class="font11">following </span>
   <span class="font11">fusion. </span>
   <span class="font11">groups. </span>
   <span class="font11">highest </span>
   <span class="font11">include </span>
   <span class="font11">includes </span>
   <span class="font11">infecting </span>
   <span class="font11">inhibitor, </span>
   <span class="font11">initial </span>
   <span class="font11">injection </span>
   <span class="font11">intermediate </span>
   <span class="font11">laboratory </span>
   <span class="font11">leading </span>
   <span class="font11">longer </span>
   <span class="font11">majority </span>
   <span class="font11">molecules </span>
   <span class="font11">mutant </span>
   <span class="font11">necessary </span>
   <span class="font11">number </span>
   <span class="font11">oral </span>
   <span class="font11">partner </span>
   <span class="font11">pocapavir </span>
   <span class="font11">polymerase </span>
   <span class="font11">postdoctoral </span>
   <span class="font11">pre-fusion </span>
   <span class="font11">primary </span>
   <span class="font11">prior </span>
   <span class="font11">programme </span>
   <span class="font11">progress </span>
   <span class="font11">progression. </span>
   <span class="font11">prolonged </span>
   <span class="font11">protease </span>
   <span class="font11">provided </span>
   <span class="font11">pt;} </span>
   <span class="font11">recent </span>
   <span class="font11">report: </span>
   <span class="font11">response. </span>
   <span class="font11">restore </span>
   <span class="font11">rose </span>
   <span class="font11">samples </span>
   <span class="font11">select </span>
   <span class="font11">series </span>
   <span class="font11">serotypes </span>
   <span class="font11">single </span>
   <span class="font11">speaker </span>
   <span class="font11">starting </span>
   <span class="font11">strain </span>
   <span class="font11">strains. </span>
   <span class="font11">study, </span>
   <span class="font11">success </span>
   <span class="font11">susceptibility </span>
   <span class="font11">tenofovir </span>
   <span class="font11">therapies </span>
   <span class="font11">therapy, </span>
   <span class="font11">tissues </span>
   <span class="font11">treatment </span>
   <span class="font11">trust </span>
   <span class="font11">types </span>
   <span class="font11">vitro </span>
   <span class="font11">widely </span>
   <span class="font11">‘back </span>
  </p>
 </body>
</html>
